LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) ATTY DOCKET NO. Y2428-00163 APPLICANT Brogmann et al. FILING DATE May 23, 2005 APPLICATION NO. 10/510,673 APPLICANT Brogmann et al.

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A06	4,126,684	11/21/1978	Robson et al.			
	A07	4,668,685	05/26/1987	Shami			
	A08	5,236,714	08/17/1993	Lee et al.			
	A09	6,258,042	07/10/2001	Factor et al.			
	A10	6,696,088	02/24/2004	Oshlack et al.			
	A11	2003/0178031	09/25/2003	DuPen et al.			
	A12	2007/0185146	08/09/2007	Fleischer et al.			

FOREIGN PATENT DOCUMENTS

 	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	ATION
						YES	NO
B14	2138593	03/30/1972	DE				
B15	1604666	12/14/2005	EP				
B16	1353815	05/22/1974	GB				
B17	1999/005960	02/11/1999	PCT				
B18	2001/058447	08/16/2001	PCT				
B19	2002/087512	11/07/2002	PCT				
B20	2002/092060	11/21/2002	PCT				
B21	2003/020124	03/13/2003	PCT				
B22	2003/073937	09/12/2003	PCT				
B23	2003/084504	10/16/2003	PCT				
B24	2003/084520	10/16/2003	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	o Hill Hall Delivers (Incoming Humor, 1 and, 1 are a gets, 1 ac.)		
C09	Clark et al., "Symptom indexes to assess outcomes of treatment for early prostate cancer" Medical Care 39(10): 1118-1130 (October, 2001).		
C10	Cohen, Statistical Power Analyses for the Behavioral Sciences (2 nd ed.) Hilsdale, NJ: Erlbaum (1988)		
C11	Deyo RA et al., "Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation." Cont. Clin. Trials 12: 142S-158S (1991).		
C12	Drossman DA et al., Rome II: The Functional Gastrointestinal Disorders (2 nd ed.) McLean, VA: Degnon Associates (2000)		
C13	Guyatt et al., "Measuring change over time: assessing the usefulness of evaluative instruments" J. Chronic Dis. 40(2): 171 178 (1987).		
C14	Guyatt et al., "Interpreting treatment effects in randomized trials" Br. Med. J. 316(7132): 690-693 (1998).		
C15	Hays et al., "Assessing reliability and validity of measurement in clinical trials" in: Staquet et al., (eds.) Quality of Life in Clinical Trials: Methods and Practice Oxford: Oxford University Press (1998).		
C08	Hussain, MA, "Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs" Pharm. Res. 5(9): 615-618 (1988).		
C16	Kazis et al., "Effects sizes for interpreting changes in health status" Med. Care 27(3 Suppl.): S178-S189 (1989).		
C17	Leidy et al., "Recommendations for evaluating the validity of quality of life claims for labelling and promotion" Value in Health 2(2): 113-127 (1999).		

	C18	Norman et al., "Interpretation of changes in health-related quality of life. The remarkable universality of half a standard deviation" Med. Care 41: 582-592 (2003).			
	C19	Nunnally et al., <u>Psychometric Theory</u> (3 rd ed.) NY: McGraw-Hill (1994).			
	C20	Revicki et al., "Recommendation on health-related quality of life research to support labelling and promotional claims in the United States" QOL Research 9(8): 887-900 (2000).			
	C21	Wyrwich et al., "Further evidence supporting an SEM-based criterion for identifying meaningful intra-indivisual changes in health-related quality of life" J. Clin. Epidemiol. 52: 861-873 (1991).			
EXAMINER			DATE CONSIDERED		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.